EP0462246A4 - Oligomeric immunoglobulins - Google Patents

Oligomeric immunoglobulins

Info

Publication number
EP0462246A4
EP0462246A4 EP19910901546 EP91901546A EP0462246A4 EP 0462246 A4 EP0462246 A4 EP 0462246A4 EP 19910901546 EP19910901546 EP 19910901546 EP 91901546 A EP91901546 A EP 91901546A EP 0462246 A4 EP0462246 A4 EP 0462246A4
Authority
EP
European Patent Office
Prior art keywords
immunoglobulins
oligomeric
oligomeric immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19910901546
Other versions
EP0462246A1 (en
Inventor
Walt W. Shuford
Linda J. Harris
Howard V. Raff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0462246A1 publication Critical patent/EP0462246A1/en
Publication of EP0462246A4 publication Critical patent/EP0462246A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19910901546 1989-11-07 1990-11-06 Oligomeric immunoglobulins Ceased EP0462246A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43270089A 1989-11-07 1989-11-07
US432700 1989-11-07

Publications (2)

Publication Number Publication Date
EP0462246A1 EP0462246A1 (en) 1991-12-27
EP0462246A4 true EP0462246A4 (en) 1992-11-25

Family

ID=23717254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910901546 Ceased EP0462246A4 (en) 1989-11-07 1990-11-06 Oligomeric immunoglobulins

Country Status (8)

Country Link
EP (1) EP0462246A4 (en)
JP (1) JPH04505709A (en)
AU (1) AU648056B2 (en)
CA (1) CA2045150A1 (en)
IE (1) IE904015A1 (en)
NZ (1) NZ236000A (en)
PT (1) PT95809A (en)
WO (1) WO1991006305A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
JPH06500780A (en) * 1990-08-31 1994-01-27 ブリストル―マイアーズ　スクイブ　カンパニー homozygous immunoglobulin
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (en) 2004-11-12 2011-04-11 젠코어 인코포레이티드 Fc VARIANTS WITH INCREASED BINDING TO FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
PL2059536T3 (en) 2006-08-14 2014-07-31 Xencor Inc Optimized antibodies that target cd19
JP5562031B2 (en) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Optimized antibody targeting HM1.24
CA2958185C (en) 2007-12-26 2020-08-25 Xencor, Inc. Fc variants with altered binding to fcrn
US8475789B2 (en) 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102369215B (en) 2009-04-02 2015-01-21 罗切格利卡特公司 Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
SG175080A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
JP5758004B2 (en) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific antibodies comprising Fv fragments stabilized by disulfides
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014009565A (en) 2012-02-10 2014-11-10 Genentech Inc Single-chain antibodies and other heteromultimers.
PE20142422A1 (en) 2012-04-05 2015-01-21 Hoffmann La Roche BI-SPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN IL 17 AND USES OF THE SAME
JP6309002B2 (en) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Methods and uses for making antibody Fc region conjugates comprising at least one binding entity that specifically binds to a target
CN104395339A (en) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
NZ701040A (en) 2012-07-04 2017-02-24 Hoffmann La Roche Covalently linked antigen-antibody conjugates
DK2869837T3 (en) 2012-07-04 2016-09-26 Hoffmann La Roche Anti-theophylline antibodies and methods of use
CA2872192A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
JPWO2015079977A1 (en) * 2013-11-26 2017-03-16 シャープ株式会社 Antibody separation method, antibody evaluation method, pharmaceutical evaluation method, and antibody two-dimensional electrophoresis kit
CA2932958A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
EP3089996B1 (en) 2014-01-03 2021-07-28 F. Hoffmann-La Roche AG Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies
AR105089A1 (en) 2015-06-24 2017-09-06 Hoffmann La Roche ANTI-TAU ANTIBODIES (pS422) HUMANIZED AND USED METHODS
CN113495141A (en) * 2020-03-20 2021-10-12 迈克生物股份有限公司 2019 novel coronavirus IgM antibody detection kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001975A1 (en) * 1987-08-24 1989-03-09 Celltech Limited Recombinant antibodies and methods for their production
EP0314161A1 (en) * 1987-10-28 1989-05-03 Bristol-Myers Squibb Company Human immunoglobulines produced by recombinant DNA techniques
WO1991019515A1 (en) * 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001975A1 (en) * 1987-08-24 1989-03-09 Celltech Limited Recombinant antibodies and methods for their production
EP0314161A1 (en) * 1987-10-28 1989-05-03 Bristol-Myers Squibb Company Human immunoglobulines produced by recombinant DNA techniques
WO1991019515A1 (en) * 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9106305A1 *

Also Published As

Publication number Publication date
AU7030391A (en) 1991-05-31
JPH04505709A (en) 1992-10-08
PT95809A (en) 1991-09-13
AU648056B2 (en) 1994-04-14
IE904015A1 (en) 1991-05-08
EP0462246A1 (en) 1991-12-27
WO1991006305A1 (en) 1991-05-16
NZ236000A (en) 1993-09-27
CA2045150A1 (en) 1991-05-08

Similar Documents

Publication Publication Date Title
EP0462246A4 (en) Oligomeric immunoglobulins
EP0547137A4 (en) Homoconjugated immunoglobulins
AU111543S (en) Can
AU108277S (en) Hedge-shears
EP0405242A3 (en) Vip-analogs ii
GB9012394D0 (en) Case
CS490790A3 (en) Chaff-cutter
IL95678A0 (en) Novel alkanophenones
GB9027137D0 (en) Processes
GB9027728D0 (en) Novel protein
GB9003724D0 (en) Toychest ii
DE4090091D2 (en) Sanitaeres wasserventil mit geraeuschdaempfung
GB8903631D0 (en) Can ends
IE894206L (en) Novel immunoglobulins
GB2246551B (en) Can manufacture
IL95679A0 (en) Novel alkanophenones
CA64463S (en) Tapeplayer
CA64817S (en) Liminaire
CA64838S (en) Automibile
IL89683A0 (en) Electrically-protected carrying case
ZA908330B (en) Steps
IE890862L (en) Mesotetraphenylporphyrin complex
IE891518L (en) Sulphur-containing eicosanoides
GB8912148D0 (en) Crates
GB8604648D0 (en) Inductors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19921008

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940307

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19950901